Edition:
India

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,446JPY
25 Sep 2017
Change (% chg)

¥27 (+1.90%)
Prev Close
¥1,419
Open
¥1,430
Day's High
¥1,447
Day's Low
¥1,428
Volume
7,667,300
Avg. Vol
7,319,210
52-wk High
¥1,688
52-wk Low
¥1,332

Chart for

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.60
Market Cap(Mil.): ¥2,935,660.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.40

Financials

  Industry Sector
P/E (TTM): -- 30.87 15.95
EPS (TTM): -- -- --
ROI: -- 14.31 15.19
ROE: -- 15.61 13.87

BRIEF-R&I affirms Astellas Pharma's rating at "AA" and says stable outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I

20 Sep 2017

Pfizer, Astellas prostate cancer drug promising in late-stage trial

Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.

14 Sep 2017

Pfizer, Astellas prostate cancer drug promising in late-stage trial

Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.

14 Sep 2017

CORRECTED-UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial

Sept 14 Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.

14 Sep 2017

Pfizer, Astellas prostate cancer drug clears late-stage trial

Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal in a late-stage trial.

14 Sep 2017

CORRECTED-Pfizer, Astellas prostate cancer drug clears late-stage trial

Sept 14 Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

14 Sep 2017

BRIEF-Astellas Pharma and Pfizer say positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide)

* Co and Pfizer Inc announced that the Phase 3 PROSPER trial evaluating XTANDI®(enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) CastrationResistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS)

14 Sep 2017

BRIEF-Pfizer, Astellas report positive top-line results from phase 3 PROSPER trial of XTANDI

* Pfizer and Astellas announce positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide) in patients with non-metastatic castration-resistant prostate cancer

14 Sep 2017

BRIEF-U.S. FDA accepts for review Astellas' supplemental NDA for mirabegron for use in combination with solifenacin succinate

* U.S. FDA accepts for review Astellas' supplemental New Drug Application for Mirabegron for use in combination with solifenacin succinate 5 mg for the treatment of overactive bladder

13 Sep 2017

BRIEF-Astellas Pharma submits application for approval of fidaxomicin for the treatment of infectious enteritis in Japan

* Says it has submitted an application for marketing approval of fidaxomicin for the treatment of infectious enteritis in Japan

31 Jul 2017

Earnings vs. Estimates